Retinopathy of prematurity: Molecular pathology and therapeutic strategies

American Journal of PharmacoGenomics

Volumn 3, Issue 4, 2003, Pages 261-277

  Mechoulam, Hadas ^a   Pierce, Eric A ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOGENIC FACTOR; ANGIOSTATIN; ANTIINFLAMMATORY AGENT; BEVACIZUMAB; BUCILLAMINE; CHONDROMODULIN 1; CORTICOSTEROID; ENDOSTATIN; ENDOTHELIAL CELL GROWTH FACTOR; GROWTH HORMONE; INTEGRIN; JB 3; LAMININ; MATRIX METALLOPROTEINASE; MIDOSTAURIN; N(G) METHYLARGININE; NONSTEROID ANTIINFLAMMATORY AGENT; OXYGEN; PEGAPTANIB; PIGMENT EPITHELIUM DERIVED FACTOR; RANIBIZUMAB; RPI 4610; RUBOXISTAURIN; SEGLITIDE; SEMAXANIB; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE; THALIDOMIDE; THROMBOSPONDIN 1; TISSUE INHIBITOR OF METALLOPROTEINASE; TOCOPHEROL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; VATALANIB; WOC 4D;

ANGIOGENESIS; ANIMAL MODEL; BASEMENT MEMBRANE; BLINDNESS; CATARACT; CENTRAL RETINA VEIN OCCLUSION; CLINICAL TRIAL; DIABETIC RETINOPATHY; DIFFERENTIAL DIAGNOSIS; DRUG EFFICACY; ETHNIC DIFFERENCE; GENETIC SUSCEPTIBILITY; GLAUCOMA; GROWTH RETARDATION; HUMAN; HYPEROXIA; IMMUNE RESPONSE; INFANT; LOW BIRTH WEIGHT; META ANALYSIS; NONHUMAN; NORRIE DISEASE; PATHOPHYSIOLOGY; PHOTODYNAMIC THERAPY; PREMATURITY; PRIORITY JOURNAL; PROLIFERATIVE RETINOPATHY; RETINA MACULA AGE RELATED DEGENERATION; RETINA NEOVASCULARIZATION; RETROLENTAL FIBROPLASIA; REVIEW; RISK FACTOR; SIDE EFFECT; UPREGULATION; VISUAL IMPAIRMENT;

ANGIOGENESIS INDUCING AGENTS; ANGIOGENESIS INHIBITORS; ANIMALS; ANTI-INFLAMMATORY AGENTS; BASEMENT MEMBRANE; DISEASE MODELS, ANIMAL; HUMANS; INFANT, NEWBORN; RETINOPATHY OF PREMATURITY; RISK FACTORS;

ANIMALIA;

EID: 0042192111     PISSN: 11752203     EISSN: None     Source Type: Journal    
DOI: 10.2165/00129785-200303040-00004     Document Type: Review

References (190)

1. Provis JM. Development of the primate retinal vasculature. Prog Retin Eye Res 2001 Nov; 20 (6): 799-821
2. Terry TL. Extreme prematurity and fibroplastic overgrowth of persisten vascular sheath behind each crystalline lens. Am J Ophthalmol 1942; 25: 203-4
3. Campbell K. Intensive oxygen therapy as a possible cause of retrolental fibroplasia: a clinical approach. Med J Aust 1951; 2: 246-50
4. Gibson DL, Sheps SB, Schechter MT, et al. Retinopathy of prematurity: a new epidemic? Pediatrics 1989 Apr; 83 (4): 486-92
5. An international classification of retinopathy of prematurity: the Committee for the Classification of Retinopathy of Prematurity. Arch Ophthalmol 1984 Aug; 102 (8): 1130-4
6. Multicenter trial of cryotherapy for retinopathy of prematurity: ophthalmological outcomes at 10 years. Arch Ophthalmol 2001 Aug; 119 (8): 1110-8
7. Reynolds JD, Dobson V, Quinn GE, et al. Evidence-based screening criteria for retinopathy of prematurity: natural history data from the CRYO-ROP and LIGHT-ROP studies. Arch Ophthahnol 2002 Nov; 120 (11): 1470-6
8. Quinn GE, Dobson V, Barr CC, et al. Visual acuity of eyes after vitrectomy for retinopathy of prematurity: follow-up at 5 1/2 years: The Cryotherapy for Retinopathy of Prematurity Cooperative Group. Ophthalmology 1996 Apr; 103 (4): 595-600
9. Raju TN, Langenberg P, Bhutani V, et al. Vitamin E prophylaxis to reduce retinopathy of prematurity: a reappraisal of published trials. J Pediatr 1997 Dec; 131 (6): 844-50
10. Saunders RA, Donahue ML, Christmann LM, et al. Racial variation in retinopathy of prematurity: the Cryotherapy for Retinopathy of Prematurity Cooperative Group. Arch Ophthalmol 1997 May; 115 (5): 604-8
11. Seiberth V, Linderkamp O. Risk factors in retinopathy of prematurity, a multivariate statistical analysis. Ophthalmologica 2000; 214 (2); 131-5
12. Mittal M, Dhanireddy R, Higgins RD. Candida sepsis and association with retinopathy of prematurity. Pediatrics 1998 Apr; 101 (4): 654-7
13. Watts P, Adams GGW, Thomas RM, et al. Intraventricular haemorrhage and stage 3 retinopathy of prematurity. Br J Ophthalmol 2000 Jun; 84 (6): 596-9
14. Holmstrom G, Broberger U, Thomassen P. Neonatal risk factors for retinopathy of prematurity: a population-based study. Acta Ophthalmol Scand 1998 Apr; 76 (2): 204-7
15. Arnold RW, Kesler K, Avila E. Susceptibility to retinopathy of prematurity in Alaskan Natives. J Pediatr Ophthalmol Strabismus 1994 May; 31 (3): 192-4
16. Ebert EM, Mukai S. Familial exudative vitreoretinopathy. Int Ophthalmol Clin 1993; 33 (2): 237-47
17. Shastry BS, Pendergast SD, Hartzer MK, et al. Identification of missense mutations in the Norrie disease gene associated with advanced retinopathy of prematurity. Arch Ophthalmol 1997 May; 115 (5): 651-5
18. Haider MZ, Devarajan LV, Al Essa M, et al. Retinopathy of prematurity: mutations in the Norrie disease gene and the risk of progression to advanced stages. Pediatr Int 2001 Apr; 43 (2): 120-3
19. Hiraoka M, Berinstein DM, Trese MT, et al. Insertion and deletion mutations in the dinucleotide repeat region of the Norrie disease gene in patients with advanced retinopathy of prematurity. J Hum Genet 2001; 46 (4): 178-81
20. Weber BH, Vogt G, Pruett RC, et al. Mutations in the tissue inhibitor of metalloproteinases-3 (TIMP3) in patients with Sorsby's fundus dystrophy. Nat Genet 1994 Dec; 8 (4): 352-6
21. Smith LE, Wesolowski E, McLellan A, et al. Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci 1994 Jan; 35 (1): 101-11
22. Chan-Ling T, Tout S, Hollander H, et al. Vascular changes and their mechanisms in the feline model of retinopathy of prematurity. Invest Ophthalmol Vis Sci 1992 Jun; 33 (7): 2128-47
23. McLeod DS, D'Anna SA, Lutty GA. Clinical and histopathologic features of canine oxygen-induced proliferative retinopathy. Invest Ophthalmol Vis Sci 1998 Sep; 39 (10): 1918-32
24. Penn JS, Henry MM, Tolman BL. Exposure to alternating hypoxia and hyperoxia causes severe proliferative retinopathy in the newborn rat. Pediatr Res 1994 Dec; 36 (6): 724-31
25. Reynaud X, Dorey CK. Extraretinal neovascularization induced by hypoxic episodes in the neonatal rat. Invest Ophthalmol Vis Sci 1994 Jul; 35 (8): 3169-77
26. Dorey CK, Aouididi S, Reynaud X, et al. Correlation of vascular permeability factor/vascular endothelial growth factor with extraretinal neovascularization in the rat. Arch Ophthalmol 1996 Oct; 114 (10): 1210-7
27. Pierce EA, Avery RL, Foley ED, et al. Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc Natl Acad Sci U S A 1995 Jan 31; 92 (3): 905-9
28. Pierce EA, Foley ED, Smith LE. Regulation of vascular endothelial growth factor by oxygen in a model of retinopathy of prematurity. Arch Ophthalmol 1996 Oct; 114 (10): 1219-28
29. Stone J, Chan-Ling T, Pe'er J, et al. Roles of vascular endothelial growth factor and astrocyte degeneration in the genesis of retinopathy of prematurity. Invest Ophthalmol Vis Sci 1996 Feb; 37 (2): 290-9
30. Young TL, Anthony DC, Pierce E, et al. Histopathology and vascular endothelial growth factor in untreated and diode laser-treated retinopathy of prematurity. J AAPOS 1997 Jun; 1 (2): 105-10
31. Alon T, Hemo I, Itin A, et al. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med 1995 Oct; 1 (10): 1024-8
32. D'Amato RJ, Loughnan MS, Flynn E, et al. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A 1994 Apr 26; 91 (9): 4082-5
33. Ng SSW, Brown M, Figg WD. Thalidomide, an antiangiogenic agent with clinical activity in cancer. Biomed Pharmacother 2002 Jun; 56 (4): 194-9
34. Belloni PN, Nicolson GL. Differential expression of cell surface glycoproteins on various organ-derived microvascular endothelia and endothelial cell cultures. J Cell Physiol 1988 Sep; 136 (3): 398-410
35. Belloni PN, Carney DH, Nicolson GL. Organ-derived microvessel endothelial cells exhibit differential responsiveness to thrombin and other growth factors. Microvasc Res 1992 Jan; 43 (1): 20-45
36. LeCouter J, Ferrara N. EG-VEGF and the concept of tissue-specific angiogenic growth factors. Semin Cell Dev Biol 2002 Feb; 13 (1): 3-8
37. Michaelson I. The mode of development of retinal vessels, with some observations on its significance for certain retinal disease. Trans Ophthalmol Soc U K 1948; 68: 137-80
38. Leung DW, Cachianes G, Kuang WJ, et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989 Dec 8; 246 (4935): 1306-9
39. Miller JW, Adamis AP, Shima DT, et al. Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am J Pathol 1994 Sep; 145 (3): 574-84
40. Behzadian MA, Wang XL, Shabrawey M, et al. Effects of hypoxia on glial cell expression of angiogenesis-regulating factors VEGF and TGF-beta. Glia 1998 Oct; 24 (2): 216-25
41. Shweiki D, Itin A, Soffer D, et al. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992 Oct 29; 359 (6398): 843-5
42. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994 Dec 1: 331 (22): 1480-7
43. Pe'er J, Shweiki D, Itin A, et al. Hypoxia-induced expression of vascular endothelial growth factor by retinal cells is a common factor in neovascularizing ocular diseases. Lab Invest 1995 Jun; 72 (6): 638-45
44. Gerber HP, Hillan KJ, Ryan AM, et al. VEGF is required for growth and survival in neonatal mice. Development 1999 Mar; 126 (6): 1149-59
45. Benjamin LE, Hemo I, Keshet E. A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. Development 1998 May: 125 (9): 1591-8
46. Berra E, Milanini J, Richard DE, et al. Signaling angiogenesis via p42/p44 MAP kinase and hypoxia. Biochem Pharmacol 2000 Oct 15; 60 (8): 1171-8
47. Jones MK, Szabo IL, Kawanaka H, et al. Von Hippel-Lindau tumor suppressor and HIF-1 alpha: new targets of NSAID inhibition of hypoxia-induced angiogenesis. FASEB J 2001 Dec; 15 (14): U171-86
48. Grant MB, Tarnuzzer RW, Caballero S. et al. Adenosine receptor activation induces vascular endothelial growth factor in human retinal endothelial cells. Circ Res 1999 Oct 15; 85 (8): 699-706
49. Takagi H, King GL, Robinson GS, et al. Adenosine mediates hypoxic induction of vascular endothelial growth factor in retinal pericytes and endothelial cells. Invest Ophthalmol Vis Sci 1996 Oct; 37 (11): 2165-76
50. Takagi H, King GL, Ferrara N, et al. Hypoxia regulates vascular endothelial growth factor receptor KDR/Flk gene expression through adenosine A2 receptors in retinal capillary endothelial cells. Invest Ophthalmol Vis Sci 1996 Jun; 37 (7): 1311-21
51. Houck KA, Ferrara N, Winer J, et al. The vascular endothelial growth-factor family: identification of a 4Th molecular-species and characterization of alternative splicing of Rna. Mol Endocrinol 1991 Dec; 5 (12): 1806-14
52. Poltorak Z, Cohen T, Sivan R, et al. VEGF (145), a secreted vascular endothelial growth factor isoform that binds to extracellular matrix. J Biol Chem 1997 Mar 14; 272 (11): 7151-8
53. Tischer E, Mitchell R, Hartman T, et al. The human gene for vascular endothelial growth-factor: multiple protein forms are encoded through alternative exon splicing. J Biol Chem 1991 Jun 25; 266 (18): 11947-54
54. Shima DT, Kuroki M, Deutsch U, et al. The mouse gene for vascular endothelial growth factor: genomic structure, definition of the transcriptional unit, and characterization of transcriptional and post-transcriptional regulatory sequences. J Biol Chem 1996 Feb 16; 271 (7): 3877-83
55. Stalmans I, Ng YS, Rohan R, et al. Arteriolar and venular patterning in retinas of mice selectively expressing VEGF isoforms. J Clin Invest 2002 Feb; 109 (3): 327-36
56. Kim I, Ryan AM, Rohan R, et al. Constitutive expression of VEGF, VEGFR-1, and VEGFR-2 in normal eyes. Invest Ophthalmol Vis Sci 1999 Aug; 40 (9): 2115-21
57. Shima DT, Gougos A, Miller JW, et al. Cloning and mRNA expression of vascular endothelial growth factor in ischemic retinas of Macaca fascicularis. Invest Ophthalmol Vis Sci 1996 Jun; 37 (7): 1334-40
58. Suzuma K, Takagi H, Otani A, et al. Increased expression of KDR/Flk-1 (VEGFR-2) in murine model of ischemia-induced retinal neovascularization. Microvasc Res 1998 Nov; 56 (3): 183-91
59. Aiello LP. Vascular endothelial growth factor: 20th-century mechanisms, 21st-century therapies. Invest Ophthalmol Vis Sci 1997 Aug; 38 (9): 1647-52
60. Gerber HP, McMurtrey A, Kowalski J, et al. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway: requirement for Flk-1/KDR activation. J Biol Chem 1998 Nov 13; 273 (46): 30336-43
61. Gliki G, Wheeler-Jones C, Zachary I. Vascular endothelial growth factor induces protein kinase C (PKC)-dependent Akt/PKB activation and phosphatidylinositol 3′-kinase-mediates PKC delta phosphorylation: role of PKC in angiogenesis. Cell Biol Int 2002; 26 (9): 751-9
62. Kroll J, Waltenberger J. A novel function of VEGF receptor-2 (KDR): rapid release of nitric oxide in response to VEGF-A stimulation in endothelial cells. Biochem Biophys Res Commun 1999 Nov 30; 265 (3): 636-9
63. Morbidelli L, Chang CH, Douglas JG, et al. Nitric oxide mediates mitogenic effect of VEGF on coronary venular endothelium. Am J Physiol 1996 Jan; 39 (1): H411-5
64. Jozkowicz A, Cooke JP, Guevara I, et al. Genetic augmentation of nitric oxide synthase increases the vascular generation of VEGF. Cardiovasc Res 2001 Sep; 51 (4): 773-83
65. Hattenbach LO, Falk B, Nurnberger F, et al. Detection of inducible nitric oxide synthase and vascular endothelial growth factor in choroidal neovascular membranes. Ophthalmologica 2002 May; 216 (3): 209-14
66. El Asrar AM, Desmet S, Meersschaert A, et al. Expression of the inducible isoform of nitric oxide synthase in the retinas of human subjects with diabetes mellitus. Am J Ophthalmol 2001 Oct; 132 (4): 551-6
67. Ando A, Yang A, Nambu H, et al. Blockade of nitric-oxide synthase reduces choroidal neovascularization. Mol Pharmacol 2002 Sep; 62 (3): 539-44
68. Ando A, Yang A, Mori K, et al. Nitric oxide is proangiogenic in the retina and choroid. J Cell Physiol 2002 Apr; 191 (1): 116-24
69. Brooks SE, Gu XL, Samuel S, et al. Reduced severity of oxygen-induced retinopathy in eNOS-deficient mice. Invest Ophthalmol Vis Sci 2001 Jan; 42 (1): 222-8
70. Sennlaub F, Courtois Y, Goureau O. Inducible nitric oxide synthase mediates the change from retinal to vitreal neovascularization in ischemic retinopathy. J Clin Invest 2001 Mar; 107 (6): 717-25
71. Ozaki H, Seo MS, Ozaki K, et al. Blockade of vascular endothelial cell growth factor receptor signaling is sufficient to completely prevent retinal neovascularization. Am J Pathol 2000 Feb; 156 (2): 697-707
72. Seo MS, Kwak N, Ozaki H, et al. Dramatic inhibition of retinal and choroidal neovascularization by oral administration of a kinase inhibitor. Am J Pathol 1999 Jun; 154 (6): 1743-53
73. Krzystolik MG, Afshari MA, Adamis AP, et al. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol 2002 Mar; 120 (3): 338-46
74. Genetech, Inc. Development pipeline: Avastin and Lucentis [online]. Available from URL: http://www.gene.com/gene/pipeline/status [Accessed 2003 Jul 5]
75. Zhu Z, Bohlen P, Witte L. Clinical development of angiogenesis inhibitors to vascular endothelial growth factor and its receptors as cancer therapeutics. Curr Cancer Drug Targets 2002 Jun; 2 (2): 135-56
76. Scappaticci FA. Mechanisms and future directions for angiogenesis-based cancer therapies. J Clin Oncol 2002 Sep 15; 20 (18): 3906-27
77. Kendall RL, Thomas KA. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci U S A 1993 Nov 15; 90 (22): 10705-9
78. Takayama K, Ueno H, Nakanishi Y, et al. Suppression of tumor angiogenesis and growth by gene transfer of a soluble form of vascular endothelial growth factor receptor into a remote organ. Cancer Res 2000 Apr 15; 60 (8): 2169-77
79. Aiello LP, Pierce EA, Foley ED, et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci U S A 1995 Nov 7; 92 (23): 10457-61
80. Robinson GS, Pierce EA, Rook SL, et al. Oligodeoxynucleotides inhibit retinal neovascularization in a murine model of proliferative retinopathy. Proc Natl Acad Sci U S A 1996 May 14; 93 (10): 4851-6
81. Preclinical and phase I. A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. Retina 2002 Apr; 22 (2): 143-52
82. Weng DE, Usman N. Angiozyme: a novel angiogenesis inhibitor. Curr Oncol Rep 2001 Mar; 3 (2): 141-6
83. LaVail MM, Yasumura D, Matthes MT, et al. Ribozyme rescue of photoreceptor cells in P23H transgenic rats: long-term survival and late-stage therapy. Proc Natl Acad Sci U S A 2000 Oct 10; 97 (21): 11488-93
84. Reich SJ, Fosnot J, Kuroki A, et al. Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model. Mol Vis 2003 May 30; 9: 210-6
85. Koyama S, Takagi H, Otani A, et al. Inhibitory mechanism of vascular endothelial growth factor (VEGF) by bucillamine. Br J Pharmacol 2002 Nov; 137 (6): 901-9
86. Yanagi Y, Tamaki Y, Obata R, et al. Subconjunctival administration of bucillamine suppresses choroidal neovascularization in rat. Invest Ophthalmol Vis Sci 2002 Nov; 43 (11): 3495-9
87. Siemeister G, Schirner M, Reusch P, et al. An antagonistic vascular endothelial growth factor (VEGF) variant inhibits VEGF-stimulated receptor autophosphorylation and proliferation of human endothelial cells. Proc Natl Acad Sci U S A 1998 Apr 14; 95 (8): 4625-9
88. Veenendaal LM, Jin H, Ran S, et al. In vitro and in vivo studies of a VEGF121/rGelonin chimeric fusion toxin targeting the neovasculature of solid tumors. Proc Natl Acad Sci U S A 2002 Jun 11; 99 (12): 7866-71
89. McLeod DS, Taomoto M, Cao J, et al. Localization of VEGF receptor-2 (KDR/Flk-1) and effects of blocking it in oxygen-induced retinopathy. Invest Ophthalmol Vis Sci 2002 Feb; 43 (2): 474-82
90. Aiello LP, George DJ, Cahill MT, et al. Rapid and durable recovery of visual function in a patient with von hippel-lindau syndrome after systemic therapy with vascular endothelial growth factor receptor inhibitor su5416. Ophthalmology 2002 Sep; 109 (9): 1745-51
91. Shih SC, Ju M, Liu N, et al. Selective stimulation of VEGFR-1 prevents oxygen-induced retinal vascular degeneration in retinopathy of prematurity. J Clin Invest 2003 Jul; 112 (1): 50-7
92. Duke Comprehensive Cancer Center. Current clincal trials at Duke [online]. Available from URL: http: //cancer.duke.edu/btc/treatment/ClinicalTrials.asp [Accessed 2003 Jul 5]
93. Danis RP, Bingaman DP, Jirousek M, et al. Inhibition of intraocular neovascularization caused by retinal ischemia in pigs by PKCbeta inhibition with LY333531. Invest Ophthalmol Vis Sci 1998 Jan; 39 (1): 171-9
94. Frank RN. Potential new medical therapies for diabetic retinopathy: protein kinase C inhibitors. Am J Ophthalmol 2002 May; 133 (5): 693-8
95. Leitges M, Schmedt C, Guinamard R, ct al. Immunodeficiency in protein kinase cbeta-deficient mice. Science 1996 Aug 9; 273 (5276): 788-91
96. Weeber EJ, Atkins CM, Selcher JC, et al. A role for the beta isoform of protein kinase C in fear conditioning. J Neurosci 2000 Aug 15; 20 (16): 5906-14
97. Ozaki H, Yu AY, Della N, et al. Hypoxia inducible factor-1alpha is increased in ischemic retina: temporal and spatial correlation with VEGF expression. Invest Ophthalmol Vis Sci 1999 Jan; 40 (1): 182-9
98. Gao G, Li Y, Gee S, et al. Down-regulation of vascular endothelial growth factor and up-regulation of pigment epithelium-derived factor: a possible mechanism for the anti-angiogenic activity of plasminogen kringle 5. J Biol Chem 2002 Mar 15; 277 (11): 9492-7
99. Meininger CJ, Schelling ME, Granger HJ. Adenosine and hypoxia stimulate proliferation and migration of endothelial cells. Am J Physiol 1988 Sep; 255 (3 Pt 2): H554-62
100. Bontemps F, Mimouni M, Van den BG. Phosphorylation of adenosine in anoxic hepatocytes by an exchange reaction catalysed by adenosine kinase, Biochem J 1993 Mar 15; 290 (Pt 3): 679-84
101. Hashimoto E, Kage K, Ogita T, et al. Adenosine as an endogenous mediator of hypoxia for induction of vascular endothelial growth factor mRNA in U-937 cells. Biochem Biophys Res Commun 1994 Oct 14; 204 (1): 318-24
102. Mino RP, Spoerri PE, Caballero S, et al. Adenosine receptor antagonists and retinal neovascularization in vivo. Invest Ophthalmol Vis Sci 2001 Dec; 42 (13): 3320-4
103. Hellstrom A, Carlsson B, Niklasson A, et al. IGF-I is critical for normal vascularization of the human retina. J Clin Endocrinol Metab 2002 Jul; 87 (7): 3413-6
104. Sharp PS, Fallon TJ, Brazier OJ, et al. Long-term follow-up of patients who underwent yttrium-90 pituitary implantation for treatment of proliferative diabetic retinopathy. Diabetologia 1987 Apr; 30 (4): 199-207
105. Hikino S, Ihara K, Yamamoto J, et al. Physical growth and retinopathy in preterm infants: involvement of IGF-I and GH. Pediatr Res 2001 Dec; 50 (6): 732-6
106. Smith LE, Kopchick JJ, Chen W, et al. Essential role of growth hormone in ischemia-induced retinal neovascularization. Science 1997 Jun 13; 276 (5319): 1706-9
107. Growth Hormone Antagonist for Proliferative Diabetic Retinopathy Study Group. The effect of a growth hormone receptor antagonist drug on proliferative diabetic retinopathy. Ophthalmology 2001 Dec; 108 (12): 2266-72
108. Lee WH, Javedan S, Bondy CA. Coordinate expression of insulin-like growth factor system components by neurons and neuroglia during retinal and cerebellar development. J Neurosci 1992 Dec; 12 (12): 4737-44
109. Lee HC, Lee KW, Chung CH, et al. IGF-I of serum and vitreous fluid in patients with diabetic proliferative retinopathy. Diabetes Res Clin Pract 1994 Jun; 24 (2): 85-8
110. Meyer-Schwickerath R, Pfeiffer A, Blum WF, et al. Vitreous levels of the insulin-like growth factors I and II, and the insulin-like growth factor binding proteins 2 and 3, increase in neovascular eye disease: studies in nondiabetic and diabetic subjects. J Clin Invest 1993 Dec; 92 (6): 2620-5
111. Hellstrom A, Perruzzi C, Ju M, et al. Low IGF-I suppresses VEGF-survival signaling in retinal endothelial cells: direct correlation with clinical retinopathy of prematurity. Proc Natl Acad Sci U S A 2001 May 8; 98 (10): 5804-8
112. Smith LE, Shen W, Perruzzi C, et al. Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor. Nat Med 1999 Dec; 5 (12): 1390-5
113. Danesi R, Agen C, Benelli U, et al. Inhibition of experimental angiogenesis by the somatostatin analogue octreotide acetate (SMS 201-995). Clin Cancer Res 1997 Feb; 3 (2): 265-72
114. Grant MB, Caballero S, Millard WJ. Inhibition of IGF-I and b B-FGF stimulated growth of human retinal endothelial cells by the somatostatin analogue, octreotide: a potential treatment for ocular neovascularization. Regul Pept 1993 Oct 20; 48 (1-2): 267-78
115. Baudouin C, Imbert F, Ettaiche M, et al, Evaluation of antiproliferative effects of the somatostatin analogue somatuline in a rabbit model of traction retinal detachment. Fundam Clin Pharmacol 1995; 9 (4): 357-65
116. Demir T, Celiker UO, Kukner A, et al. Effect of Octreotide on experimental corneal neovascularization. Acta Ophthalmol Scand 1999 Aug; 77 (4): 386-90
117. Averbukh E, Halpert M, Yanko R, et al. Octreotide, a somatostatin analogue, fails to inhibit hypoxia-induced retinal neovascularization in the neonatal rat. Int J Exp Diabetes Res 2000; 1 (1): 39-47
118. Higgins RD, Yan Y, Schrier BK. Somatostatin analogs inhibit neonatal retinal neovascularization. Exp Eye Res 2002 May; 74 (5): 553-9
119. Grant MB, Mames RN, Fitzgerald C, et al. The efficacy of octreotide in the therapy of severe nonproliferative and early proliferative diabetic retinopathy: a randomized controlled study. Diabetes Care 2000 Apr; 23 (4): 504-9
120. Sierra-Honigmann MR, Nath AK, Murakami C, et al. Biological action of leptin as an angiogenic factor. Science 1998 Sep 11; 281 (5383): 1683-6
121. Park HY, Kwon HM, Lim HJ, et al. Potential role of leptin in angiogenesis: leptin induces endothelial cell proliferation and expression of matrix metalloproteinases in vivo and in vitro. Exp Mol Med 2001 Jun 30; 33 (2): 95-102
122. Uckaya G, Ozata M, Bayraktar Z, et al. Is leptin associated with diabetic retinopathy? Diabetes Care 2000 Mar; 23 (3): 371-6
123. Suganami E, Takagi H, Suzuma K, et al. Essential role of leptin in ischemia-induced retinal neovascularization. Invest Ophthalmol Vis Sci 2002; 43 (4): E-Abstract 2405
124. Mukaida N. Interleukin-8: an expanding universe beyond neutrophil chemotaxis and activation. Int J Hematol 2000 Dec; 72 (4): 391-8
125. Antonelli-Orlidge A, Saunders KB, Smith SR, et al. An activated form of transforming growth factor beta is produced by cocultures of endothelial cells and pericytes. Proc Natl Acad Sci U S A 1989 Jun; 86 (12): 4544-8
126. Lashkari K, Hirose T, Yazdany J, et al. Vascular endothelial growth factor and hepatocyte growth factor levels are differentially elevated in patients with advanced retinopathy of prematurity. Am J Pathol 2000 Apr; 156 (4): 1337-44
127. Takagi H, Suzuma K, Otani A, et al. Role of vitronectin receptor-type integrins and osteopontin in ischemia-induced retinal neovascularization. Jpn J Ophthalmol 2002 May; 46 (3): 270-8
128. Friedlander M, Theesfeld CL, Sugita M, et al. Involvement of integrins alpha v beta 3 and alpha v beta 5 in ocular neovascular diseases. Proc Natl Acad Sci U S A 1996 Sep 3; 93 (18): 9764-9
129. Luna J, Tobe T, Mousa SA, et al. Antagonists of integrin alpha v beta 3 inhibit retinal neovascularization in a murine model. Lab Invest 1996 Oct; 75 (4): 563-73
130. Hammes HP, Brownlee M, Jonczyk A, et al. Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor-type integrins inhibits retinal neovascularization. Nat Med 1996 May; 2 (5): 529-33
131. Riecke B, Chavakis E, Bretzel RG, et al. Topical application of integrin antagonists inhibits proliferative retinopathy. Horm Metab Res 2001 May; 33 (5): 307-11
132. Gutheil JC, Campbell TN, Pierce PR, et al. Targeted antiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin alphavbeta3. Clin Cancer Res 2000 Aug; 6 (8): 3056-61
133. Stitt AW, McKenna D, Simpson DA, et al. The 67-kd laminin receptor is preferentially expressed by proliferating retinal vessels in a murine model of ischemic retinopathy. Am J Pathol 1998 May, 152 (5): 1359-65
134. Gebarowska D, Stitt AW, Gardiner TA, et al. Synthetic peptides interacting with the 67-kd laminin receptor can reduce retinal ischemia and inhibit hypoxia-induced retinal neovascularization. Am J Pathol 2002 Jan; 160 (1): 307-13
135. Brinckerhoff CE, Matrisian LM. Matrix metalloproteinases: a tail of a frog that became a prince. Nat Rev Mol Cell Biol 2002 Mar; 3 (3): 207-14
136. Majka S, McGuire P, Colombo S, et al. The balance between proteinases and inhibitors in a murine model of proliferative retinopathy. Invest Ophthalmol Vis Sci 2001 Jan; 42 (1): 210-5
137. Anand-Apte B, Pepper MS, Voest F, et al. Inhibition of angiogenesis by tissue inhibitor of metalloproteinase-3. Invest Ophthalmol Vis Sci 1997 Apr; 38 (5): 817-23
138. Qi JH, Ebrahem Q, Yeow K, et al. Expression of Sorsby's fundus dystrophy mutations in human retinal pigment epithelial cells reduces matrix metalloproteinase inhibition and may promote angiogenesis. J Biol Chem 2002 Apr 19; 277 (16): 13394-400
139. Auricchio A, Behling KC, Maguire AM, et al. Inhibition of retinal neovascularization by intraocular viral-mediated delivery of anti-angiogenic agents. Mol Ther 2002 Oct; 6 (4): 490-4
140. Brooks PC, Silletti S, von Schalscha TL, et al. Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity. Cell 1998 Feb 6; 92 (3): 391-400
141. Rudek MA, Figg WD, Dyer V, et al. Phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer. J Clin Oncol 2001 Jan 15; 19 (2): 584-92
142. Tombran-Tink J, Chader GG, Johnson LV. PEDF: a pigment epithelium-derived factor with potent neuronal differentiative activity. Exp Eye Res 1991 Sep; 53 (3): 411-4
143. O'Reilly MS, Holmgren L, Shing Y, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994 Oct 21; 79 (2): 315-28
144. O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997 Jan 24; 88 (2): 277-85
145. Cao Y. Endogenous angiogenesis inhibitors and their therapeutic implications. Int J Biochem Cell Biol 2001 Apr; 33 (4): 357-69
146. EntreMed, Inc. Angiogenesis inhibitors now in human clinical trials [online]. Available from URL: http://www.entremed.com/pipeline.cfm [Accessed 2003 Jul 5]
147. Herbst RS, Hess KR, Tran HT, et al. Phase I study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol 2002 Sep 15; 20 (18): 3792-803
148. Karakousis PC, John SK, Behling KC, et al. Localization of pigment epithelium derived factor (PEDF) in developing and adult human ocular tissues. Mol Vis 2001 Jun 30; 7: 7154-63
149. Dawson DW, Volpert OV, Gillis P, et al. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science 1999 Jul 9; 285 (5425): 245-8
150. Duh EJ, Yang HS, Suzuma I, et al. Pigment epithelium-derived factor suppresses ischemia-induced retinal neovascularization and VEGF-induced migration and growth. Invest Ophthalmol Vis Sci 2002 Mar; 43 (3): 821-9
151. Stellmach V, Crawford SE, Zhou W, et al. Prevention of ischemia-induced retinopathy by the natural ocular antiangiogenic agent pigment epithelium-derived factor. Proc Natl Acad Sci U S A 2001 Feb 27; 98 (5): 2593-7
152. Mori K, Duh E, Gehlbach P, et al. Pigment epithelium-derived factor inhibits retinal and choroidal neovascularizadon. J Cell Physiol 2001 Aug; 188 (2): 253-63
153. Raisler BJ, Berns KI, Grant MB, et al. Adeno-associated virus type-2 expression of pigmented epithelium-derived factor or Kringles 1-3 of angiostatin reduce retinal neovascularization. Proc Natl Acad Sci U S A 2002 Jun 25; 99 (13): 8909-14
154. GenVec, Inc. PEDF program - a new approach to prevent blindness [online]. Available from URL: http: //www.genvec.com/products_gene_therapy_pedf.-asp [Accessed 2003 Jul 5]
155. Rasmussen H, Chu KW, Campochiaro P, et al. Clinical protocol: a open-label, phase I, single administration, dose-escalation study of ADGVPEDF.11D (ADPEDF) in neovascular age-related macular degeneration (AMD). Hum Gene Ther 2001 Nov 1; 12 (16): 2029-32
156. Cao Y, Ji RW, Davidson D, et al. Kringle domains of human angiostatin: characterization of the anti-proliferative activity on endothelial cells. J Biol Chem 1996 Nov 15; 271 (46): 29461-7
157. Spranger J, Hammes HP, Preissner KT, et al. Release of the angiogenesis inhibitor angiostatin in patients with proliferative diabetic retinopathy: association with retinal photocoagulation. Diabetologia 2000 Nov; 43 (11): 1404-7
158. Drixler TA, Rinkes IH, Ritchie ED, et al. Angiostatin inhibits pathological but not physiological retinal angiogenesis. Invest Ophthalmol Vis Sci 2001 Dec; 42 (13): 3325-30
159. Fukai N, Eklund L, Marneros AG, et al. Lack of collagen XVIII/endostatin results in eye abnormalities. EMBO J 2002 Apr 2; 21 (7): 1535-44
160. Noma H, Funatsu H, Yamashita H, et al. Regulation of angiogenesis in diabetic retinopathy: possible balance between vascular endothelial growth factor and endostatin. Arch Ophthalmol 2002 Aug; 120 (8): 1075-80
161. Mori K, Ando A, Gehlbach P, et al. Inhibition of choroidal neovascularization by intravenous injection of adenoviral vectors expressing secretable endostatin. Am J Pathol 2001 Jul; 159 (1): 313-20
162. Jimenez B, Volpert OV, Crawford SE, et al. Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. Nat Med 2000 Jan; 6 (1): 41-8
163. Suzuma K, Takagi H, Otani A, et al. Expression of thrombospondin-1 in ischemia-induced retinal neovascularization. Am J Pathol 1999 Feb; 154 (2): 343-54
164. Shafiee A, Penn JS, Krutzsch HC, et al. Inhibition of retinal angiogenesis by peptides derived from thrombospondin-1. Invest Ophthalmol Vis Sci 2000 Jul; 41 (8): 2378-88
165. Hiraki Y, Tanaka H, Inoue H, et al. Molecular cloning of a new class of cartilage-specific matrix, chondromodulin-I, which stimulates growth of cultured chondrocytes. Biochem Biophys Res Commun 1991 Mar 29; 175 (3): 971-7
166. Hiraki Y, Inoue H, Iyama K, et al. Identification of chondromodulin I as a novel endothelial cell growth inhibitor: purification and its localization in the avascular zone of epiphyseal cartilage. J Biol Chem 1997 Dec 19; 272 (51): 32419-26
167. Hiraki Y, Kono T, Sato M, et al. Inhibition of DNA synthesis and tube morphogenesis of cultured vascular endothelial cells by chondromodulin-I. FEBS Lett 1997 Oct 6; 415 (3): 321-4
168. Hayami T, Shukunami C, Mitsui K, et al. Specific loss of chondromodulin-I gene expression in chondrosarcoma and the suppression of tumor angiogenesis and growth by its recombinant protein in vivo. FEBS Lett 1999 Sep 24; 458 (3): 436-40
169. Funaki H, Sawaguchi S, Yaoeda K, et al. Expression and localization of angiogenic inhibitory factor, chondromodulin-I, in adult rat eye. Invest Ophthalmol Vis Sci 2001 May; 42 (6): 1193-200
170. Penfold PL, Madigan MC, Gillies MC, et al. Immunological and aetiological aspects of macular degeneration. Prog Retin Eye Res 2001 May; 20 (3): 385-414
171. Higgins RD, Mendelsohn AL, DeFeo MJ, et al. Antenatal dexamethasone and decreased severity of retinopathy of prematurity. Arch Ophthalmol 1998 May; 116 (5): 601-5
172. Yossuck P, Yan Y, Tadesse M, et al. Dexamethasone and critical effect of timing on retinopathy. Invest Ophthalmol Vis Sci 2000 Sep; 41 (10): 3095-9
173. Ishibashi T, Miki K, Sorgente N, et al. Effects of intravitreal administration of steroids on experimental subretinal neovascularization in the subhuman primate. Arch Ophthalmol 1985 May; 103 (5): 708-11
174. Lawas-Alejo PA, Slivka S, Hernandez H, et al. Hyperoxia and glucocorticoid modify retinal vessel growth and interleukin-1 receptor antagonist in newborn rabbits. Pediatr Res 1999 Mar; 45 (3): 313-7
175. Crum R, Szabo S, Folkman J. A new class of steroids inhibits angiogenesis in the presence of heparin or a heparin fragment. Science 1985 Dec 20; 230 (4732): 1375-8
176. Penn JS, Rajaratnam VS, Collier RJ, et al. The effect of an angiostatic steroid on neovascularization in a rat model of retinopathy of prematurity. Invest Ophthalmol Vis Sci 2001 Jan; 42 (1): 283-90
177. Alcon Research Ltd. Information about a clinical trial sponsored by Alcon Research Ltd to evaluate an experimental treatment for wet AMD [online]. Available from URL: http: //www.alconlabs.com/us/eo/clinicalStudies/AMD/C0199.jhtml [Accessed 2003 Jul 5]
178. Wang YS, Friedrichs U, Eichler W, et al. Inhibitory effects of triamcinolone acetonide on bFGF-induced migration and tube formation in choroidal microvascular endothelial cells. Graefes Arch Clin Exp Ophthalmol 2002 Jan; 240 (1): 42-8
179. Danis RP, Bingaman DP, Yang Y, et al. Inhibition of preretinal and optic nerve head neovascularization in pigs by intravitreal triamcinolone acetonide. Ophthalmology 1996 Dec; 103 (12): 2099-104
180. Nandgaonkar BN, Rotschild T, Yu K, et al. Indomethacin improves oxygen-induced retinopathy in the mouse. Pediatr Res 1999 Aug; 46 (2): 184-8
181. Takahashi K, Saishin Y, Saishin Y, et al. Topical nepafenac inhibits ocular neovascularization. Invest Ophthalmol Vis Sci 2003 Jan; 44 (1): 409-15
182. Bennett J, Maguire AM, Cideciyan AV, et al. Stable transgene expression in rod photoreceptors after recombinant adeno-associated virus-mediated gene transfer to monkey retina. Proc Natl Acad Sci U S A 1999 Aug 17; 96 (17): 9920-5
183. Auricchio A, Rivera VM, Clackson T, et al. Pharmacological regulation of protein expression from adeno-associated viral vectors in the eye. Mol Ther 2002 Aug; 6 (2): 238-42
184. Chowers I, Banin E, Hemo Y, et al. Gene transfer by viral vectors into blood vessels in a rat model of retinopathy of prematurity. Br J Ophthalmol 2001 Aug; 85 (8): 991-5
185. Mori K, Gehlbach P, Ando A, et al. Intraocular adenoviral vector-mediated gene transfer in proliferative retinopathies. Invest Ophthalmol Vis Sci 2002 May; 43 (5): 1610-5
186. Bainbridge JW, Mistry A, Binley K, et al. Hypoxia-regulated transgene expression in experimental retinal and choroidal neovascularization. Gene Ther 2003 Jun; 10 (12): 1049-54
187. Mechoulam H, Pierce EA. Gene expression profile of ischemia-induced retinal neovascularization. Invest Ophthalmol Vis Sci 2002 Apr; 43 (4): E-Abstract 1275
188. Sato A, Shibuki H, Kikuchi T, et al. Gene microaaray analysis of retina in a mouse model of oxygen-induced retinopathy. Invest Ophthalmol Vis Sci 2002 Apr; 43 (4): E-Abstract 3707
189. Yu JL, Rak JW, Coomber BL, et al. Effect of p53 status on tumor response to antiangiogenic therapy. Science 2002 Feb 22; 295 (5559): 1526-8
190. Bressler NM, Bressler SB. Photodynamic therapy with verteporfin (Visudyne): impact on ophthalmology and visual sciences. Invest Ophthalmol Vis Sci 2000 Mar; 41 (3): 624-8